[en] Early treatment and combining a triptan with a non-steroidal anti-inflammatory drug (NSAID) are thought to improve outcome during migraine attacks, possibly by counteracting the negative influence of cutaneous allodynia. The aim of this multicentre, double-blind pilot study was to evaluate the prevalence of brush allodynia and its relative influence on the efficacy of a triptan-NSAID combination compared with headache intensity at the time of treatment. In a randomized, cross-over design, 112 migraineurs treated two moderate or severe attacks with almotriptan 12.5 mg combined with either aceclofenac 100 mg or placebo. Patients used a 2-cm brush to assess cutaneous allodynia. Allodynia was reported in 34.4% of attacks. The almotriptan-aceclofenac combination was numerically superior to triptan-placebo on 2-24-h sustained pain-free (P = 0.07), 2-h pain-free (P = 0.07) and headache recurrence (P = 0.05) rates, but not on 1-h headache relief. Allodynia numerically reduced treatment success overall, but this effect was not significant for the primary outcome measures. Headache intensity had a significant negative influence on 1-h relief in both attacks (P = 0.0001 and 0.0008, chi(2)) and on 2-24-h sustained pain-free rates in triptan-placebo-treated attacks (P = 0.013). Multivariate logistic regression analysis confirmed that headache intensity at treatment intake, rather than allodynia, significantly influenced most outcome measures, predominantly so in attacks treated with almotriptan and aceclofenac. In the latter, severe compared with moderate headache intensity reduced the likelihood of achieving the primary efficacy end-points [odds ratios (OR) 0.12 and 0.33], whereas allodynia was not a significant explanatory variable (OR 0.76 and 0.65). The results apply to the protocol used here and need to be confirmed in larger studies using quantitative sensory testing.
Disciplines :
Neurology
Author, co-author :
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
De Klippel, N.
Giurgea, S.
Herroelen, L.
Jacquy, J.
Louis, P.
Monseu, G.
Vandenheede, M.
Language :
English
Title :
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.
Publication date :
2008
Journal title :
Cephalalgia
ISSN :
0333-1024
eISSN :
1468-2982
Publisher :
Blackwell Science, Osney Mead Oxford, United Kingdom
Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000 47 : 614 24.
Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack - clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000 123 (Pt 8 1703 9.
Goadsby PJ. Recent advances in the diagnosis and management of migraine. BMJ 2006 332 : 25 9.
Yamamura H, Malick A, Chamberlin NL, Burstein R. Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol 1999 81 : 479 93.
Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 55 : 19 26.
Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006 26 : 113 21.
Linde M, Elam M, Lundblad L, Olausson H, Dahlof CG. Sumatriptan (5-HT1B/1D-agonist) causes a transient allodynia. Cephalalgia 2004 24 : 1057 66.
Schoenen J. When should triptans be taken during a migraine attack? CNS Drugs 2001 15 : 583 7.
Jelinski SE, Becker WJ, Christie SN, Ahmad FE, Pryse-Phillips W, Simpson SD. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 2006 33 : 73 9.
Cady R, Martin V, Mauskop A, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Efficacy of Rizatriptan 10 mg administered early in a migraine attack. Headache 2006 46 : 914 24.
Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 2007 47 : 189 98.
Ferrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia 2004 24 : 915 17.
Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 2005 45 : 973 82.
Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995 346 : 923 6.
Ghelardini C, Galeotti N, Grazioli I, Uslenghi C. Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. J Pain 2004 5 : 413 19.
Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 45 : 850 61.
Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002 22 : 309 12.
Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004 4 : 10.
Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005 45 : 983 91.
Brandes JL, Kudrow D, Stark SR, O'Carrol CP, Adelman J, O'Donnell FJ et al. Sumatriptan-naproxen for acute treatment of migraine - a randomized trial. JAMA 2007 297 : 1443 54.
Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ et al. Guidelines for controlled trials of drugs in migraine, 2nd edn. Cephalalgia 2000 20 : 765 86.
Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979 8 : 7 20.
Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 2004 63 : 848 52.
Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology 2005 65 : 1419 22.
Landy S, McGinnis JE, McDonald SA. Clarification of developing and established clinical allodynia and pain-free outcomes. Headache 2007 47 : 247 52.
LoPinto C, Young WB, Ashkenazi A. Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia 2006 26 : 852 6.
Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia 2007 27 : 111 17.
Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960 23 : 23 32.
Fuseau E, Petricoul O, Sabin A, Pereira A, O'Quinn S, Thein S et al. Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther 2001 23 : 242 51.